10-Q quarterly report · filed Nov 10, 2026

Protalix BioTherapeutics, Inc. (PLX) Q3 2026 10-Q Quarterly Report

Short answer

Protalix BioTherapeutics, Inc. (PLX) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $22M (up 22.8% year over year) with net income of $4M.

Q3 2026 key financials · XBRL

Revenue
$22M
+22.8% YoY · +10.2% QoQ
Net income
$4M
+68.2% YoY · +4.9% QoQ
Operating margin
18.5%
EPS (diluted)
$0.04
+33.3% YoY · −20.0% QoQ

Source: XBRL data from the Protalix BioTherapeutics, Inc. (PLX) Q3 2026 10-Q on SEC EDGAR. USD.

Protalix BioTherapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $21.925M, up from $17.851M YoY, driven by selling-goods revenue of $21.834M
  • Q3 operating margin 18.5% vs 11.9% YoY, with operating income $4.047M vs $2.131M
  • Best segment Chiesi, Q3 sales $13.138M vs $8.763M; worst Fiocruz, $4.365M vs $6.105M
  • Cash and short-term deposits $48.5M; nine-month operating cash flow $15.529M vs $(14.023)M YoY
  • Management expects rising R&D spending for the RELEASE study, with funds sufficient for at least 12 months

Risk Factors

  • No material changes to previously disclosed risk factors in the 2025 Form 10-K
  • No material changes to risk factors reported in the June 30, 2026 Form 10-Q

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Protalix BioTherapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.